RegCell Secures $66 Million of Additional Funding to Bring Nobel-Winning Immune Tolerance Science to the Clinic

Combined financing will enable IND submission and advance RegCell’s next-generation epigenetic reprogramming platform into a second autoimmune indication through Phase 2 as proof of concept.